全文获取类型
收费全文 | 150877篇 |
免费 | 9557篇 |
国内免费 | 2287篇 |
专业分类
耳鼻咽喉 | 2263篇 |
儿科学 | 2266篇 |
妇产科学 | 2147篇 |
基础医学 | 22650篇 |
口腔科学 | 3476篇 |
临床医学 | 15003篇 |
内科学 | 25522篇 |
皮肤病学 | 4492篇 |
神经病学 | 11317篇 |
特种医学 | 8004篇 |
外国民族医学 | 16篇 |
外科学 | 18221篇 |
综合类 | 5094篇 |
现状与发展 | 7篇 |
一般理论 | 32篇 |
预防医学 | 9045篇 |
眼科学 | 3893篇 |
药学 | 14346篇 |
48篇 | |
中国医学 | 3074篇 |
肿瘤学 | 11805篇 |
出版年
2024年 | 131篇 |
2023年 | 1240篇 |
2022年 | 3892篇 |
2021年 | 5940篇 |
2020年 | 3290篇 |
2019年 | 3776篇 |
2018年 | 4574篇 |
2017年 | 3968篇 |
2016年 | 4699篇 |
2015年 | 6747篇 |
2014年 | 8052篇 |
2013年 | 9085篇 |
2012年 | 13654篇 |
2011年 | 13188篇 |
2010年 | 7736篇 |
2009年 | 6613篇 |
2008年 | 8961篇 |
2007年 | 8373篇 |
2006年 | 7424篇 |
2005年 | 6838篇 |
2004年 | 5751篇 |
2003年 | 4995篇 |
2002年 | 4236篇 |
2001年 | 3275篇 |
2000年 | 3024篇 |
1999年 | 2366篇 |
1998年 | 1020篇 |
1997年 | 787篇 |
1996年 | 582篇 |
1995年 | 544篇 |
1994年 | 446篇 |
1993年 | 377篇 |
1992年 | 829篇 |
1991年 | 764篇 |
1990年 | 687篇 |
1989年 | 594篇 |
1988年 | 495篇 |
1987年 | 499篇 |
1986年 | 349篇 |
1985年 | 391篇 |
1984年 | 268篇 |
1983年 | 203篇 |
1982年 | 140篇 |
1981年 | 174篇 |
1980年 | 132篇 |
1979年 | 234篇 |
1978年 | 168篇 |
1976年 | 138篇 |
1974年 | 146篇 |
1973年 | 125篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
Rodrigo Rodrigues Pessoa Paul Maroni Janet Kukreja Simon P. Kim 《Translational andrology and urology》2021,10(5):2158
Radical prostatectomy (RP) has undergone a remarkable transformation from open to minimally-invasive surgery over the last two decades. However, it is important to recognize there is still conflicting evidence regarding key outcomes. We aimed to summarize current literature on comparative effectiveness of robotic and open RP for key outcomes including oncologic results, health-related quality of life (HRQOL) measures, safety and postoperative complications, and healthcare costs. The bulk of the paper will discuss and interpret limitations of current data. Finally, we will also highlight future directions of both surgical approaches and its potential impact on health care delivery. 相似文献
992.
Louise B. Russell Sun-Young Kim Cristiana Toscano Ben Cosgriff Ruth Minamisava Ana Lucia Andrade Colin Sanderson Anushua Sinha 《Vaccine》2021,39(1):158-166
BackgroundThis paper compares cost-effectiveness results from two models of maternal immunization to prevent pertussis in infants in Brazil, one static, one dynamic, to explore when static models are adequate for public health decisions and when the extra effort required by dynamic models is worthwhile.MethodsWe defined two scenarios to explore key differences between static and dynamic models, herd immunity and time horizon. Scenario 1 evaluates the incremental cost/DALY of maternal acellular pertussis (aP) immunization as routine infant vaccination coverage ranges from low/moderate up to, and above, the threshold at which herd immunity begins to eliminate pertussis. Scenario 2 compares cost-effectiveness estimates over the models’ different time horizons. Maternal vaccine prices of $9.55/dose (base case) and $1/dose were evaluated.ResultsThe dynamic model shows that maternal immunization could be cost-saving as well as life-saving at low levels of infant vaccination coverage. When infant coverage reaches the threshold range (90–95%), it is expensive: the dynamic model estimates that maternal immunization costs $2 million/DALY at infant coverage > 95% and maternal vaccine price of $9.55/dose; at $1/dose, cost/DALY is $200,000. By contrast, the static model estimates costs/DALY only modestly higher at high than at low infant coverage. When the models’ estimates over their different time horizons are compared at infant coverage < 90–95%, their projections fall in the same range.ConclusionsStatic models may serve to explore an intervention’s cost-effectiveness against infectious disease: the direction and principal drivers of change were the same in both models. When, however, an intervention too small to have significant herd immunity effects itself, such as maternal aP immunization, takes place against a background of vaccination in the rest of the population, a dynamic model is crucial to accurate estimates of cost-effectiveness. This finding is particularly important in the context of widely varying routine infant vaccination rates globally.Clinical Trial registryClinical Trial registry name and registration number: Not applicable. 相似文献
993.
目的探讨儿童身体脂肪分布与维生素D营养状况的关系。方法研究对象来自“儿童青少年心血管与骨健康促进项目”2017年北京基线调查。采用多重线性回归和无序多分类logistic回归分析BMI、全身体脂肪质量指数(FMI)、躯干脂肪质量指数(TFMI)、四肢脂肪质量指数(AFMI)和内脏脂肪面积(VFA)与维生素D水平及营养状况的关系。结果共纳入11960名儿童[年龄(11.0±3.3)岁,男童占49.7%]进行分析,血清25(OH)D水平为(35.0±11.9)nmol/L,维生素D缺乏率为37.2%。BMI、FMI、TFMI和AFMI与维生素D的关联性具有性别差异(交互P<0.05),在男童中呈负相关(BMI:β=-0.56;FMI:β=-0.59;TFMI:β=-0.60;AFMI:β=-0.59;均P<0.05),在女童中关联无统计学意义(均P>0.05)。VFA与维生素D缺乏和不足风险在男女童中均呈正相关,VFA每增加1个标准差,维生素D缺乏和不足的患病风险均增加17%(95%CI:9%~25%)。结论儿童内脏脂肪水平越高维生素D水平越低,腹型肥胖儿童和体脂肪过多的男童是维生素D缺乏防控的重点人群。 相似文献
994.
Charlotte V. Hobbs Jan Drobeniuc Theresa Kittle John Williams Paul Byers Panayampalli S. Satheshkumar Kengo Inagaki Meagan Stephenson Sara S. Kim Manish M. Patel Brendan Flannery CDC COVID- Response Team CDC COVID- Response Team Bailey Alston Shanna J. Bolcen Darbi Boulay Peter Browning Li Cronin Ebenezer David Tonya Hayden Han Li Travis Lim Panagiotis Maniatis Palak Patel Mathew Pauly Amanda Poe Lili Punkova Vera Semenova Evelene P. Steward-Clark Alexandra Tejada Briana Zellner 《MMWR. Morbidity and mortality weekly report》2021,70(9):312
995.
Soo Jeong Choi Ki Chang Nam Sooin Choi Jin Kuk Kim You Kyoung Lee Bum Sun Kwon 《Health policy (Amsterdam, Netherlands)》2021,125(7):941-946
Medical devices may revolutionize healthcare delivery but can lead to serious adverse events for treated patients and users. While reporting of adverse events related to medical devices is an essential starting point for post-market surveillance, underreporting of medical device adverse events is a global problem. Korea introduced a voluntary medical device adverse event reporting system in 2010, called the Medical Device Safety Information Monitoring Center, which has led to an increase in adverse event reports. For 10 years, the Medical Device Safety Information Monitoring Center has analyzed medical device adverse events systematically and has provided active feedback to the manufacturers and education on safe use. Recently, the Medical Device Safety Information Monitoring Center contributed to harmonization of international medical device vigilance through the sharing of adverse events. This experience of Korea might contribute to improvements in medical device vigilance, which is a critical prerequisite for improving medical device policies and regulations. 相似文献
996.
Wanitchaya Kittikraisak Podjanee Phadungkiatwatana Darunee Ditsungnoen Surasak Kaoiean Louis Macareo Kamonthip Rungrojcharoenkit Nattinee Srisantiroj Tawee Chotpitayasunondh Fatimah S. Dawood Joshua A. Mott Kim A. Lindblade 《Vaccine》2021,39(1):18-25
BackgroundWe compared cord blood antibody titers in unvaccinated pregnant women to those vaccinated with seasonal influenza vaccine during the 2nd and the 3rd trimesters.MethodsPregnant women had cord blood collected at delivery for hemagglutination inhibition assay against vaccine reference viruses: A/California/07/2009 (H1N1)pdm09, A/Switzerland/9715293/2013 (H3N2), and B/Phuket/3073/2013 (Yamagata lineage). Geometric mean titer (GMT) ratios were calculated comparing vaccinated versus unvaccinated pregnant women, and women vaccinated in the 2nd and the 3rd trimesters. Proportions of women achieving defined titers were compared using the χ2 test.ResultsOf 307 women, 190 (62%) were unvaccinated. Fifty and 67 were vaccinated during the 2nd and the 3rd trimesters, respectively. Median enrollment age was 29 years (interquartile range 24–34). Sixteen (5%) women had pre-existing conditions, but none were immunocompromised. GMT ratios comparing vaccinated and unvaccinated women were 5.90 (95% confidence interval [CI] 5.06–6.96) for influenza A/California, 5.39 (95% CI 4.18–6.08) for influenza A/Switzerland, and 5.05 (95% CI 4.43–5.85) for influenza B/Phuket. Similarly, the GMT ratios comparing the 3rd and the 2nd trimester vaccinated women were 2.90 (95% CI 2.54–3.39), 2.82 (95% CI 2.56–3.13), and 2.83 (95% CI 2.56–3.14), respectively. The proportions of women with defined titers for the three vaccine reference viruses did not differ between 2nd and 3rd trimester vaccinated women (titers ≥40: 68–92% versus 70–93%; ≥110: 32% versus 33–63%; and ≥330: 4–10% versus 3–21%).ConclusionsPregnant women vaccinated against influenza had more placental transfer of influenza antibodies to their infants than unvaccinated women. Placental transfer of antibodies was higher among those vaccinated in the 3rd trimester than in the 2nd trimester. There was no difference in the proportions of women achieving antibody titers corresponding to protection against influenza in children. Findings support the current World Health Organization’s recommendation that pregnant women may be vaccinated in either 2nd or 3rd trimester of pregnancy. 相似文献
997.
998.
Mouillet Guillaume Falcoz Antoine Fritzsch Joëlle Almotlak Hamadi Jacoulet Pascale Pivot Xavier Villanueva Cristian Mansi Laura Kim Stefano Curtit Elsa Meneveau Nathalie Adotevi Olivier Jary Marine Eberst Guillaume Vienot Angelique Calcagno Fabien Pozet Astrid Djoumakh Oumelkheir Borg Christophe Westeel Virginie Anota Amélie Paget-Bailly Sophie 《Quality of life research》2021,30(11):3255-3266
Quality of Life Research - Routine Electronic Monitoring of Health-Related Quality of Life (HRQoL) (REMOQOL) in clinical care with real-time feedback to physicians could help to enhance... 相似文献
999.
Elligson Richard L. Childs Kristina K. Gryglewicz Kim 《The journal of primary prevention》2021,42(6):549-565
Journal of Prevention - Youth Mental Health First Aid (YMHFA) is a gatekeeper training designed to assist professionals in their identification and response to youth mental illness. Despite... 相似文献
1000.
Grace Montepiedra Ritesh Ramchandani Sachiko Miyahara Soyeon Kim 《Statistics in medicine》2021,40(2):327-348
When a new treatment regimen is expected to have comparable or slightly worse efficacy to that of the control regimen but has benefits in other domains such as safety and tolerability, a noninferiority (NI) trial may be appropriate but is fraught with difficulty in justifying an acceptable NI margin that is based on both clinical and statistical input. To overcome this, we propose to utilize composite risk‐benefit outcomes that combine elements from domains of importance (eg, efficacy, safety, and tolerability). The composite outcome itself may be analyzed using a superiority framework, or it can be used as a tool at the design stage of a NI trial for selecting an NI margin for efficacy that balances changes in risks and benefits. In the latter case, the choice of NI margin may be based on a novel quantity called the maximum allowable decrease in efficacy (MADE), defined as the marginal difference in efficacy between arms that would yield a null treatment effect for the composite outcome given an assumed distribution for the composite outcome. We observe that MADE: (1) is larger when the safety improvement for the experimental arm is larger, (2) depends on the association between the efficacy and safety outcomes, and (3) depends on the control arm efficacy rate. We use a numerical example for power comparisons between a superiority test for the composite outcome vs a noninferiority test for efficacy using the MADE as the NI margin, and apply the methods to a TB treatment trial. 相似文献